Celularity, Inc. is a clinical-stage biotechnology company headquartered in Florham Park, New Jersey, that specializes in the development and commercialization of allogeneic “off-the-shelf” cell therapies derived from postpartum placental cells. Leveraging a proprietary platform of placental- and umbilical-derived cells, the company seeks to deliver immune-modulatory, regenerative and anti-inflammatory treatments across oncology, immunology and other therapeutic areas. By harnessing the natural properties of placental cells, Celularity aims to overcome the limitations of autologous therapies and scale production to serve a broad patient population.
The company’s pipeline includes CYNK-001, an investigational natural killer (NK) cell therapy being evaluated for hematological malignancies and solid tumors, as well as other cell-based programs targeting viral infections and tissue repair. Celularity’s manufacturing network in New Jersey and Pennsylvania is designed to support large-scale production under current Good Manufacturing Practice (cGMP) conditions. Through strategic partnerships and collaborations, the company is advancing its lead candidates into clinical trials while exploring new indications for its placental-derived cell assets.
Founded in 2017 as a spin-out from Celgene Cellular Therapeutics, Celularity was co-founded by Dr. Robert Hariri, who serves as Chairman and Chief Executive Officer, together with pioneering stem cell scientist Michael West. Under their leadership, the company has raised capital from both institutional investors and industry partners to fund its research, manufacturing expansion and regulatory efforts. Celularity’s executive team combines experience in cell therapy R&D, biologics manufacturing and clinical development, positioning the company to pursue a range of novel therapies.
While Celularity’s primary operations are based in the United States, the company has expressed plans to explore international collaborations and expand its footprint through licensing agreements and co-development partnerships. With a focus on scalable, allogeneic platforms, Celularity aims to translate the unique biological properties of placental cells into accessible treatments for patients worldwide.
AI Generated. May Contain Errors.
